Incidence of Wernicke- encephalopathy appeared quite low among patients with myeloproliferative neoplasms treated with fedratinib, according to study results presented at ASH Annual Meeting and Exposition.An analysis of nine trials that included 877 patients with myeloproliferative neoplasms or solid tumors treated with fedratinib (Impact Biomedicines) showed there were one
Idasanutlin demonstrated clinical activity among patients with refractory polycythemia vera, according to study results presented at ASH Annual Meeting and Exposition.The agent also appeared well tolerated.
The investigational activin receptor IIA ligand trap sotatercept safely increases hemoglobin levels in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis, both when used alone and in combination with ruxolitinib (Jakafi).
Treatment with pegylated interferon alfa-2a led to objective responses in about two-thirds of patients with hydroxyurea (Hydrea)-resistant/intolerant polycythemia vera (PV) or high-risk essential thrombocytopenia (ET), a phase II study of salvage therapy showed.
The JAK1 inhibitor ruxolitinib is the only therapy approved by the U.S. Food and Drug Administration for myelofibrosis (MF), but it often worsens anemia, which is common in myeloproliferative neoplasm (MPN)-associated MF. According to data presented at the 2017 ASH Annual Meeting, the fusion protein sotatercept improves anemia symptoms in patients with MPN-associated MF, both as a single agent ...
Dec 11th, 2017 - Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.
This video highlights results of a phase I study of idasanutlin (RG7388) in patients with refractory polycythemia vera and essential thrombocythemia.
This video highlights a study that establishes mutated CALR as a myeloproliferative neoplasms–specific tumor antigen and provides a rationale for the development of immunotherapies targeting mutated CALR.
The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV).
May 11th, 2017 - A novel pegylated formulation of interferon alfa-2b achieved a significantly higher rate of complete hematologic response (CHR) compared with hydroxyurea (Hydrea) in patients with polycythemia vera (PV), according to 2-year findings from the follow-up phase III CONTI-PV randomized trial.
Feb 1st, 2018 - The MDM2 antagonist idasanutlin was well tolerated and demonstrated “clear clinical activity” in patients with polycythemia vera (PV) and essential thrombocythemia (ET) that was resistant or intolerant to standard therapy, according to results from a phase I study presented at the 2017 ASH Annual Meeting.
Dec 11th, 2017 - Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.
Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.
This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.